Business Context and Reporting Period
This Form 8-K filing by Coherus BioSciences, Inc. (CHRS) was submitted on February 12, 2021, reporting events occurring on February 8, 2021. The filing addresses Item 5.02 regarding the departure of a Chief Financial Officer and the appointment of a successor.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive personnel changes and does not contain financial performance data.
Material Changes
- Resignation: Jean-Frédéric Viret, Ph.D., resigned as Chief Financial Officer and from his employment with the Company, effective March 7, 2021.
- Appointment: McDavid Stilwell was appointed as the new Chief Financial Officer, effective March 8, 2021.
- Reason for Departure: Dr. Viret's resignation is to pursue a new opportunity and is not due to any disagreement with the Company regarding operations, financial statements, internal controls, or policies.
Outlook, Risks, and Management Commentary
The Company anticipates entering into a new employment arrangement and a standard indemnification agreement with Mr. Stilwell. The indemnification agreement will cover expenses such as attorneys' fees and judgments incurred in actions arising from his services as an executive officer. No specific risks, contingencies, or unusual items related to financial performance were disclosed in this filing.
Investor Verification Checklist
- Verify the effective dates of the CFO transition (March 7 and March 8, 2021).
- Confirm the absence of any disagreement between the departing CFO and the Company regarding financial reporting or internal controls.
- Review the new employment and indemnification agreements filed as exhibits to understand compensation and liability terms for the new CFO.
- Check subsequent filings for the first financial report prepared under the new CFO's tenure.